TUXUMDON SARATONI VA QORIN BO’SHLIG’I KARTSINOMATOZNING III VA IV BOSQICHLARIDA QON-TOMIR ENDOTELIAL O‘SISH OMILI (VEGF) ROLI
##article.subject##:
tuxumdon saratoni, peritoneal kartsinomatoz, tomir endotelial o‘sish omili (VEGF), o‘sma angiogenezi, biomarker, prognoz##article.abstract##
Tuxumdon saratoni, ayniqsa peritoneal kartsinomatoz (PK) bilan bog‘liq III va IV bosqichlarda davolash va prognozlashda jiddiy qiyinchiliklarni keltirib chiqaradi. Tomir endotelial o‘sish omili (VEGF) o‘sma angiogenezining asosiy regulyatori sifatida aniqlangan bo‘lib, u o‘smaning rivojlanishi, metastazlanishi va terapiyaga chidamliligiga yordam beradi. Ushbu tadqiqotning maqsadi tuxumdon saratoni bilan kasallangan bemorlarning plazma va peritoneal suyuqligidagi VEGF kontsentratsiyasini baholash va uning prognozli ahamiyatini o‘rganishdan iborat edi. Tadqiqotga 35 nafar bemor jalb qilindi va ularga sitoreduktiv jarrohlik amaliyoti o‘tkazildi, VEGF darajasi fermentativ immunoanaliz (ELISA) usuli bilan baholandi. Bundan tashqari, yuqori VEGF ekspressiyasi kasallikning IV bosqichida yomon prognoz, qisqargan retsidivsiz va umumiy omon qolish bilan bog‘liq ekanligi aniqlandi. Ushbu natijalar VEGFni tuxumdon saratonida peritoneal kartsinomatoz bilan bog‘liq potentsial prognoz biomarkeri va terapevtik nishon sifatida muhimligini ta’kidlaydi. Bemorlarning natijalarini yaxshilash uchun VEGFga qarshi yo‘naltirilgan strategiyalarni chuqur o‘rganish zarur.
Библиографические ссылки
Ferrara N. VEGF: an update on biological and therapeutic aspects. Nature Medicine. 2019;25(6):946-958.
Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine. 1971;285(21):1182-1186.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine. 2011;365(26):2473-2483.
OH Ubaydullayevna, EB Sobirovna, SN Yusupovna //The optimization of early diagnosis of cervical cancer and its recurrences - Conferencea, 2023
OH Ubaydullayevna, EB Sobirovna, MM Bakhtiyorovich//Prediction and study of the occurrence of cervical cancer recurrence International Journal of Medical Sciences And Clinical Research 3 (04), 121-124
Esankulova Bustonoy Sobirovna, Ulmasov Firdavs Gayratovich//Analysis of the tumor microenvironment of ovarian tumors using immunohistochemistry// Биология ва тиббиёт муаммолари 2024, №5 (156)
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Nodir RM, Shaxnoza SS, Farhod R. Development of new approaches in the treatment of metastatic renal cell carcinoma //Journal of research in health science. – 2020. – T. 5. – no. 4. – pp. 82-95.
ShSh Shakhanova , NM Rakhimov. Multimodal approach to the treatment of multiple osteogenic metastases of kidney and prostate cancer . Clinical and Experimental Oncology 2020, No. 4 Page 50-56.
Ulmasov F.G., Esankulova B.S. Immunohistochemical study of the ovarian cancer microenvironment at different stages: the role of immune cells in tumor progression // Journal of Biomedicine and Practice. 2024, vol. 9, issue 5, pp.
